PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Clonixin→

Clonixin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
17737-65-4
Molecular formula
C13H11ClN2O2
Molecular weight
262.69 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)nicotinic-acid derivative
Mechanism of action
The molecular mechanism is not fully characterised. As an NSAID, its pharmacology is presumed to include cyclo-oxygenase-mediated reduction of prostaglandin synthesis, contributing to analgesic and anti-inflammatory effects; this should be regarded as a class-based mechanism rather than a fully established compound-specific target profile.
Indications / reported uses
  • Management of pain and inflammation associated with chronic arthritic conditions and selected soft-tissue disorders in jurisdictions where clonixin is authorised

Sources: PubChem compound summary (includes MeSH class information and a note that molecular mechanism is incompletely investigated) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Clonixin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Clonixin Permitted Daily Exposure (PDE) report (the Clonixin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Clonixin Occupational Exposure Limit (OEL) report (the Clonixin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.